Deupirfenidone

PureTech's deupirfenidone demonstrated potential to stabilize lung function decline over 26 weeks in idiopathic pulmonary fibrosis patients, an unprecedented achievement in IPF treatment.

Pliant Therapeutics has temporarily suspended enrollment and dosing in its Phase IIb/III BEACON-IPF trial of Bexotegrast following recommendations from the independent Data Safety Monitoring Board.

Recent clinical trials have shown promising results for treatments in idiopathic pulmonary fibrosis, inflammatory bowel disease, and early Parkinson’s disease, while a sciatica treatment failed to meet expectations.

Boehringer Ingelheim's nerandomilast met its primary endpoint in the Phase III FIBRONEER-ILD trial, improving lung function in patients with progressive pulmonary fibrosis.

Insilico Medicine's ISM001-055 met its primary safety endpoint and secondary efficacy endpoints in a Phase IIa trial for idiopathic pulmonary fibrosis (IPF).